YU89891A - SMEŠE TGF-beta - Google Patents

SMEŠE TGF-beta

Info

Publication number
YU89891A
YU89891A YU89891A YU89891A YU89891A YU 89891 A YU89891 A YU 89891A YU 89891 A YU89891 A YU 89891A YU 89891 A YU89891 A YU 89891A YU 89891 A YU89891 A YU 89891A
Authority
YU
Yugoslavia
Prior art keywords
beta
tgf
linoleic
omega
combination
Prior art date
Application number
YU89891A
Other languages
English (en)
Inventor
Michael James Hewman
Original Assignee
F.Hoffmann-La Roche Ag. Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag. Basel filed Critical F.Hoffmann-La Roche Ag. Basel
Publication of YU89891A publication Critical patent/YU89891A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SMEŠE TGF-beta, terapeutska aktivnost beta-faktora fransformacije rasta (TGF-beta) protiv neoplazijskih bolesti, a naročito protiv karcinoma i melanoma, povećava se njegovim korišćenjem u kombinaciji sa sinergistički efektivnom količinom polinezasićene masne kiseline (PUFA) ili njenog derivata. U poželjnom obliku izvodjenja, tip 1 beta-faktora transformacije rasta (TGF-beta 1) ispoljava povećanu antineoplazijsku aktivnost kada se koristi u kombinaciji sa omega-3 ili omega-6 polinezasićenom masnom kiselinom, kao što su linolna, alfa-linolna, arahidonska, guma-linolna, dihomogama-linolna, ejkozapentapelargonska i dokozaheksapelargonska kiselina.
YU89891A 1990-05-22 1991-05-21 SMEŠE TGF-beta YU89891A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/527,215 US5147854A (en) 1990-05-22 1990-05-22 Tgf-b compositions and method

Publications (1)

Publication Number Publication Date
YU89891A true YU89891A (sh) 1994-06-10

Family

ID=24100576

Family Applications (1)

Application Number Title Priority Date Filing Date
YU89891A YU89891A (sh) 1990-05-22 1991-05-21 SMEŠE TGF-beta

Country Status (16)

Country Link
US (1) US5147854A (sh)
EP (1) EP0462398A1 (sh)
JP (1) JPH05213772A (sh)
KR (1) KR910019638A (sh)
AU (1) AU636489B2 (sh)
CA (1) CA2042973A1 (sh)
FI (1) FI912462A (sh)
HU (1) HUT57599A (sh)
IE (1) IE911736A1 (sh)
IL (1) IL98177A0 (sh)
MC (1) MC2259A1 (sh)
NO (1) NO911949L (sh)
NZ (1) NZ238179A (sh)
PT (1) PT97728A (sh)
YU (1) YU89891A (sh)
ZA (1) ZA913647B (sh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248666A (en) * 1984-03-23 1993-09-28 Oncogen Methods for inhibiting neoplastic cell proliferation using platelet factor 4
US4890152A (en) * 1986-02-14 1989-12-26 Matsushita Electric Works, Ltd. Plastic molded chip carrier package and method of fabricating the same
US5824297A (en) * 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
US5817625A (en) * 1992-09-21 1998-10-06 Oncogene Science, Inc. Methods of prevention of oral mucositis with transforming growth factor beta
AU687767B2 (en) * 1992-12-01 1998-03-05 Oy Biotie Therapies Ltd Syndecan stimulation of cellular differentiation
US5726058A (en) * 1992-12-01 1998-03-10 Jalkanen; Markku Syndecan stimulation of cellular differentiation
DE4304394A1 (en) * 1993-02-13 1993-09-02 Fresenius Ag Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins
US6017727A (en) * 1994-03-07 2000-01-25 Biotie Therapies Ltd. Syndecan enhancer element and syndecan stimulation of cellular differentiation
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
WO1998004680A1 (en) * 1996-07-26 1998-02-05 University Of Manitoba Serum-free medium for growth of anchorage-dependant mammalian cells
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US20020141995A1 (en) * 1997-06-10 2002-10-03 Irvin Charles G. Method for treatment of inflammatory disease
US6248723B1 (en) 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
US5891925A (en) * 1997-06-27 1999-04-06 Abbott Laboratories Diagnostic method for assessing the serum cholesterol response to low diets
WO2001024812A1 (en) * 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
US6767541B2 (en) * 2000-03-20 2004-07-27 The Regents Of The University Of California HER-2/neu overexpression abrogates growth inhibitory pathways
US6689810B2 (en) * 2001-08-21 2004-02-10 Cellular Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US20040229791A1 (en) * 2002-12-31 2004-11-18 Jung San Huang Compositions and methods of modulating TGF-beta activity by fatty acids
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
US20060186078A1 (en) * 2005-02-22 2006-08-24 David Ziegenhorn Screw on dispensing closure with structure for preventing removal
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.
GB0704678D0 (en) * 2007-03-09 2007-04-18 Univ Bristol Pro- and anti-angiogenic treatments
WO2009029656A1 (en) * 2007-08-27 2009-03-05 Auxagen, Inc. METHODS FOR INHIBITING TGF-β
PL2285242T3 (pl) * 2008-06-10 2013-09-30 Dsm Ip Assets Bv Kombinacje ekstraktu roślinnego i PUFA
US8487006B2 (en) * 2008-09-16 2013-07-16 Auxagen, Inc. Method of enhancing TGF-β signalling
US10322125B2 (en) 2013-02-22 2019-06-18 Emory University TGF-beta enhancing compositions for cartilage repair and methods related thereto

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4326055A (en) * 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4816442A (en) * 1986-11-07 1989-03-28 Collagen Corporation Method of inhibiting tumor growth sensitive to CIF-βtreatment

Also Published As

Publication number Publication date
IL98177A0 (en) 1992-06-21
FI912462A0 (fi) 1991-05-21
KR910019638A (ko) 1991-12-19
ZA913647B (en) 1992-02-26
HUT57599A (en) 1991-12-30
FI912462A (fi) 1991-11-23
US5147854A (en) 1992-09-15
CA2042973A1 (en) 1991-11-23
IE911736A1 (en) 1991-12-04
PT97728A (pt) 1992-02-28
EP0462398A1 (en) 1991-12-27
NO911949D0 (no) 1991-05-21
AU7713991A (en) 1991-12-12
AU636489B2 (en) 1993-04-29
JPH05213772A (ja) 1993-08-24
NZ238179A (en) 1993-04-28
HU911672D0 (en) 1991-11-28
NO911949L (no) 1991-11-25
MC2259A1 (fr) 1993-04-26

Similar Documents

Publication Publication Date Title
YU89891A (sh) SMEŠE TGF-beta
DE69720787D1 (de) Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
NZ217703A (en) 2-(2-fluoro-4-biphenylyl) propionic acid compositions
IT1235879B (it) Composizione di acidi grassi comprendente almeno 80% in peso di acidi grassi poliinsaturi omega-3
NO940277L (no) Triglycerider og blandinger av slike
DE3486235D1 (de) Fettsäure-Zusammensetzungen.
ATE43242T1 (de) Pharmazeutische oder diaetetische zusammensetzung mit hoher antithrombotischer und antiarteriosklerotischer wirkung.
DK0623019T3 (da) Medikamenter på basis af docosahexaensyre som midler mod blodpladeaggregation og mod cerebral mangel på essentielle fedtsyr
DE3875286D1 (de) Essentielle fettsaeure enthaltende zusammensetzungen.
SE7410757L (sh)
AU554413B2 (en) Linoleic acid and essential fatty acid compositions as
NO932843L (no) Farmasoeytiske preparater
SE8800990L (sv) Hudregenererande kosmetisk komposition samt foerfarande foer framstaellning av densamma
ATE67664T1 (de) Verwendung von linol- oder linolensaeuremetaboliten zur behandlung vom praemenstruellen syndrom.
RU95102525A (ru) Смесь омега-3 полиненасыщенных жирных кислот